Charles River places its proposal to merge with China’s WuXi PharmaTech in front of its shareholders, while ClinTec and Synexus …
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

